Effectiveness and Safety Profile of Cisplatin Versus Nab-Paclitaxel Concomitant Chemoradiotherapy in Postoperative Early-Stage Cancer of the Cervix

This study compared the effectiveness and safety of cisplatin versus nab-paclitaxel in 100 women with early-stage cervical cancer undergoing postoperative chemoradiotherapy. Both treatments showed similar overall survival (OS) and progression-free survival (PFS) rates, with 2-year OS at 98% for cisplatin and 97% for nab-paclitaxel, and PFS at 98% for both groups. However, cisplatin was associated with higher hematological and gastrointestinal toxicity, while nab-paclitaxel led to more alopecia. The study concludes that nab-paclitaxel is an effective alternative to cisplatin, offering comparable survival outcomes with a better safety profile.